Share this post on:

product name Tasisulam


Description: Tasisulam is an antitumor agent that induced growth arrest and apoptosis of human solid tumours. In human malignant hematopoietic cell lines, tasisulam inhibited cells growth with ED50 values of 5, 7, 12, 13, 21 and 31 μM for BALL1, HL60, RCH, NCEB1, SP49 and Daudi cell lines, respectively. Tasisulam induced growth arrest in a dose-dependent way. Also, tasisulam caused induction of ROS, loss of mitochondrial membrane potential and induction of apoptosis. In HL60 and U937 cells, tasisulam induce granulocytic/monocytic differentiation. 

Reference: Oncol Rep. 2008 Nov;20(5):1237-42.



Molecular Weight (MW)

415.11
Formula

C11H6BrCl2NO3S2
CAS No.

519055-62-0
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 83 mg/mL (199.94 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol:
Solubility (In vivo)

 

other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1940485

General In mice bearing the Calu-6 non-small cell lung xenograft model, tasisulam exhibited antitumor efficacy in a dose-dependent way and reduced tumor volume by 77%. Tasisulam caused G2-M accumulation and increased nuclear fragmentation. Also, tasisulam induced vascular normalization.
Animal model  Calu-6 non–small cell lung xenograft model
Formulation  saline
Dosages  50 mg/kg
Administration  i.v.
Reference [1] Meier T, et al. Mol Cancer Ther. 2011, 10(11), 2168-2178.

EGF816